Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...
It does not apply to 1.7 mg or 2.4 mg semaglutide (Wegovy), which is indicated for chronic weight management. Chronic kidney disease is a common complication of type 2 diabetes; around 40% ...
With thousands of press releases published each week, it can be difficult to keep up with everything on . To help journalists ...
Pathologist Dr Margot Bolster said Breeda O’Donoghue's death should be referred to the Health Products Regulatory Authority ...
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...
Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback